In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews, June 2014

Executive Summary

Profiles of AdverseEvents, AventaMed, Ensysce Biosciences, Jounce Therapeutics, LensGen, Marvao Medical Devices, Pharmasum Therapeutics, and Rotation Medical.

You may also be interested in...



AventaMed Ltd.

More than 2.2 million cases of otitis media with effusion are diagnosed each year worldwide, with as many as 90% of children having at least one episode by age 10. The standard treatment is surgical placement of tiny tympanostomy tubes to ventilate the middle ear space, but AventaMed Ltd. is working to dramatically reduce costs in treating OME and to improve the patient experience with a novel device for tympanostomy tube placement that takes less than one second in an office setting.

Rotation Medical Inc.

Rotation Medical Inc.’s implantable collagen scaffold induces formation of new tendon-like tissue, and in some cases eliminates the need for suture anchors in surgical repair. This new technique has the potential to prevent rotator cuff disease progression and significantly reduce the incidence of re-tears.

Marvao Medical Devices Ltd.

Catheter-related bloodstream infections are the bane of tunneled dialysis catheters, despite the widespread use of antimicrobial dressings or an injection cap placed on the exit site of the catheter to help protect the inside of the catheter from becoming colonized. The NexSite Hemodialysis Catheter from Marvao Medical Devices Ltd. is designed to reduce these bloodstream infections with a protective biomaterial tissue ingrowth scaffold that is part of the catheter and positioned at the skin exit site.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel